L'intérêt à découvert pour 10x Genomics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de 10x Genomics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

10x Genomics (NASDAQ:TXG) Stock, Rapport sur les intérêts à découvert

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

S&P/TSX GlbMn US

S&P/TSX Global Gold Index (USD)

S&P/TSX Global Gold Index (USD) (TR)

WIIM

FIVN

Five9 shares are trading higher after the company announced it expanded its global presence through new data centers in Delhi and Mumbai. Additionally, the company secured a DOT certification to offer access and long-distance services in India.

Lake Street analyst Robert Brown maintains LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) with a Buy and lowers the price target from $9 to $6.

News

Price Target

Analyst Ratings

LIQT

Lake Street Maintains Buy on LiqTech Intl, Lowers Price Target to $6

Cinemark Holdings shares are trading higher after Roth MKM and Wells Fargo raised their respective price targets on the stock.

Looking at gold, it remains in a very strong uptrend, though it has paused due to the impressive recovery in the US dollar. The dollar could continue to see more upside, especially given that inflation came in a bit stickier at 2.4% rather than the expected 2.3%. However, even if the dollar strengthens after the next pullback, there's still a chance that gold will resume its uptrend. Remember, if inflation remains elevated and doesn't trend downward, gold could be seen as an inflation hedge. Additionally, gold tends to perform well during times of geopolitical risk, like the current issues in the Middle East.
In terms of the wave count, we're seeing a very nice three-wave retracement in gold back to the 2600 level, which is a key level from mid-September when the Fed cut rates by 50 basis points. This level could now serve as a good area for the next swing to the upside. Ideally, this push higher could occur in the fifth wave, especially if the price breaks above the 2635 resistance, markets as bullish level, which could open the door to 2700.
On the downside, the channel support is critical, but the most important level for identifying a potential top would be a break below 2532. Only then could we say the top is in place, as this would invalidate the uptrend based on Elliott Wave rules, which dictate that wave 4 must not fall into the territory of wave 1.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="800" height="751" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1.png" alt="" class="wp-image-2172" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1.png 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1-300x282.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1-768x721.png 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
Trade Well,
Grega Horvat
Forex Analytix

Commodities

Trading Ideas

General

Gold Has More Upside After This Pullback

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are currently competing for a seat at an elite table: The <a href="https://www.benzinga.com/news/24/07/39674237/tsmcs-market-cap-hits-1-trillion-whats-going-on-with-the-stock">exclusive trillion-dollar club</a>. 
Taiwan Semiconductor&#8217;s market cap first crossed the <a href="https://www.benzinga.com/news/24/07/39733017/taiwan-semiconductor-joins-the-trillion-dollar-club-surpassing-tesla-report">trillion-dollar threshold in July</a>. It has since contracted to roughly $820 billion — a stone&#8217;s throw away from Broadcom&#8217;s $867 billion. 
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) are among the club&#8217;s current members after their market caps exceeded a trillion dollars, fueled <a href="https://www.benzinga.com/topic/artificial-intelligence">by AI advancements</a>.
With TSM and Broadcom both driving critical innovations in AI semiconductors, we ask: Which company&#8217;s market cap will attain nine zeros next?
<h2 class="wp-block-heading">TSMC: AI-Driven Chipmaker Poised For Growth</h2>
Taiwan Semiconductor stands as the world's largest contract chipmaker, leading the market with its 3nm and 5nm technology. These chips are integral for AI workloads, fueling AI giants like Nvidia and Apple.
This has propelled TSM's stock by over 83.3% year-to-date and 105.39% in the past year.
Analysts from Needham and Susquehanna maintain Overweight ratings, with an average price target of $236.67, implying 27.15% upside. A price at that level would push TSM's market cap to over $1.23 trillion, positioning it to re-join the trillion-dollar club.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM.png" alt="" class="wp-image-589674" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM-300x217.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, TSMC is also in a bullish trend with buying pressure across its eight, 20, 50 and 200-day moving averages, all signaling continued upward momentum. 
TSM&#8217;s stock currently trades at $186.33, supported by a simple moving average, or SMA, (50-day) of $170.55 and a SMA (200-day) of $149.54, indicating positive technical indicators.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41245350/nvidia-poised-to-overtake-apple-as-worlds-most-valuable-company-how-much-jensen-huangs-company-n">Nvidia Poised To Overtake Apple As World&#8217;s Most Valuable Company</a>
<h2 class="wp-block-heading">Broadcom: AI Infrastructure Play With Solid Momentum</h2>
Broadcom is capitalizing on the AI boom through its extensive semiconductor solutions for data centers, networking infrastructure, and real-time analytics. 
Its stock is up 69.28% year-to-date and 114.05% in the past year. Despite bullish ratings, its projected upside falls short of TSM. Analysts from Cantor Fitzgerald, Truist Securities, and UBS see AVGO reaching $200, implying an 8.80% upside, which would push its market cap to $934 billion.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM.png" alt="" class="wp-image-589675" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM-300x217.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, Broadcom is also trending positively, with its current price of $184.40 supported by moving averages, such as its 50-day SMA of $161.82 and 200-day SMA of $142.55. However, it still lags behind TSM's stronger growth trajectory.
<h2 class="wp-block-heading">TSMC Could Outpace Broadcom In the Trillion-Dollar Race</h2>
While both stocks are positioned to benefit from AI, TSMC has the edge, with superior technical indicators and greater market cap potential. 
With an imminent leap toward $1.23 trillion in market cap if it meets analysts&#8217; upside potential, TSM appears more likely to reach the trillion-dollar club before Broadcom.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41271262/broadcom-micron-traders-get-new-tools-with-direxions-latest-leveraged-bull-and-bear-etfs">Broadcom, Micron Traders Get New Tools With Direxion&#8217;s Latest Leveraged Bull And Bear ETFs</a></li>
</ul>

Technicals

Tech

AAPL

AVGO

MSFT

NVDA

Taiwan Semiconductor Vs. Broadcom: Who Will Be The Next Trillion-Dollar AI Giant?

Live On CNBC, Kevin Simpson Announces Sold Walmart Covered Call

BMO Capital analyst David Gagliano maintains Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) with a Market Perform and raises the price target from $25 to $26.

BMO Capital Maintains Market Perform on Peabody Energy, Raises Price Target to $26

Investors with a lot of money to spend have taken a bullish stance on NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NEE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for NextEra Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $174,303, and 3 are calls, for a total amount of $190,320.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $95.0 for NextEra Energy over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for NextEra Energy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextEra Energy's whale activity within a strike price range from $80.0 to $95.0 in the last 30 days. 
<h3>NextEra Energy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577326_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$6.35</td>
<td>$6.1</td>
<td>$6.35</td>
<td>$82.50</td>
<td>$101.6K</td>
<td>2.0K</td>
<td style="text-align: right;">169</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$95.00</td>
<td>$46.7K</td>
<td>635</td>
<td style="text-align: right;">147</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.35</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$82.50</td>
<td>$42.0K</td>
<td>4.6K</td>
<td style="text-align: right;">218</td>
</tr>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.81</td>
<td>$2.7</td>
<td>$2.81</td>
<td>$80.00</td>
<td>$41.5K</td>
<td>3.1K</td>
<td style="text-align: right;">152</td>
</tr>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.73</td>
<td>$0.67</td>
<td>$0.69</td>
<td>$80.00</td>
<td>$34.5K</td>
<td>8.6K</td>
<td style="text-align: right;">587</td>
</tr>
</tbody>
</table>

<h3>About NextEra Energy</h3>
NextEra Energy's regulated utility, Florida Power &amp; Light, is the largest rate-regulated utility in Florida. The utility distributes power to nearly 6 million customer accounts in Florida and owns 34 gigawatts of generation. FP&amp;L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 34 GW of generation capacity, including natural gas, nuclear, wind, and solar.
After a thorough review of the options trading surrounding NextEra Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of NextEra Energy</h3>
<ul>
<li>Trading volume stands at 2,865,668, with NEE's price up by 1.13%, positioned at $81.49.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>Professional Analyst Ratings for NextEra Energy</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $85.66666666666667.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $87. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on NextEra Energy with a target price of $80. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for NextEra Energy, targeting a price of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for NextEra Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Market Whales and Their Recent Bets on NEE Options

High-rolling investors have positioned themselves bearish on ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ADMA often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 14 options trades for ADMA Biologics. This is not a typical pattern.
The sentiment among these major traders is split, with 21% bullish and 71% bearish. Among all the options we identified, there was one put, amounting to $40,000, and 13 calls, totaling $467,143.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $14.0 to $17.5 for ADMA Biologics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ADMA Biologics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ADMA Biologics's whale trades within a strike price range from $14.0 to $17.5 in the last 30 days. 
<h3>ADMA Biologics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577321_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.8</td>
<td>$2.4</td>
<td>$2.8</td>
<td>$17.50</td>
<td>$56.0K</td>
<td>3.5K</td>
<td>818</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.75</td>
<td>$2.15</td>
<td>$2.75</td>
<td>$17.50</td>
<td>$55.0K</td>
<td>3.5K</td>
<td>618</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$5.5</td>
<td>$4.4</td>
<td>$4.95</td>
<td>$14.00</td>
<td>$49.5K</td>
<td>120</td>
<td>103</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.2</td>
<td>$2.0</td>
<td>$2.2</td>
<td>$17.50</td>
<td>$44.0K</td>
<td>3.5K</td>
<td>214</td>
</tr>
<tr>
<td>ADMA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.5</td>
<td>$0.2</td>
<td>$0.5</td>
<td>$15.00</td>
<td>$40.0K</td>
<td>1</td>
<td>2.6K</td>
</tr>
</tbody>
</table>

<h3>About ADMA Biologics</h3>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Having examined the options trading patterns of ADMA Biologics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>ADMA Biologics's Current Market Status</h3>
<ul>
<li>With a volume of 12,172,914, the price of ADMA is down -18.28% at $16.61. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for ADMA Biologics</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $20. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ADMA Biologics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ADMA

This Is What Whales Are Betting On ADMA Biologics

Harmony Gold Mining shares are trading higher after JP Morgan upgraded the stock from Underweight to Neutral and raised its price target from $4.9 to $8.2.

Whales with a lot of money to spend have taken a noticeably bullish stance on CVS Health.
Looking at options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $179,610 and 10, calls, for a total amount of $1,201,272.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $70.0 for CVS Health over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for CVS Health options trades today is 5602.57 with a total volume of 29,356.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CVS Health's big money trades within a strike price range of $60.0 to $70.0 over the last 30 days.
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577316_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$0.9</td>
<td>$0.79</td>
<td>$0.9</td>
<td>$69.00</td>
<td>$450.0K</td>
<td>108</td>
<td>4</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.02</td>
<td>$63.00</td>
<td>$189.1K</td>
<td>5.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$65.00</td>
<td>$139.6K</td>
<td>6.0K</td>
<td>943</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/11/24</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.44</td>
<td>$63.00</td>
<td>$119.0K</td>
<td>5.1K</td>
<td>285</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$63.00</td>
<td>$106.3K</td>
<td>5.1K</td>
<td>6.6K</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
Having examined the options trading patterns of CVS Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,013,488, with CVS's price up by 1.35%, positioned at $66.86.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>What The Experts Say On CVS Health</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $73.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on CVS Health, which currently sits at a price target of $75. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $62. 
&#x2A; In a positive move, an analyst from Barclays has upgraded their rating to Overweight and adjusted the price target to $82. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $62. 
&#x2A; An analyst from TD Cowen upgraded its action to Buy with a price target of $85. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About CVS Health

Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) shares are trading higher On Thursday. The company disclosed the appointment of a new<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41271264/cloudflare-appoints-chirantan-cj-desai-as-president-of-product-engineering-continues-strong-leader" rel="noreferrer noopener"> president of product &amp; engineering</a>.
In particular, the company appointed Chirantan &#8220;CJ&#8221; Desai as President of Product &amp; Engineering to further accelerate its next phase of growth towards $5 billion in annual recurring revenue.
Desai most recently served as President and Chief Operating Officer at ServiceNow, where he managed the company's products, platform, design, AI research, engineering, customer support, cloud infrastructure operations, and customer success.
Matthew Prince, co-founder &amp; CEO at Cloudflare, said, &#8220;CJ&#8217;s track record of driving innovation, operational excellence, and customer-centric growth speaks for itself and makes him an ideal fit for Cloudflare as we continue to scale our company and push the boundaries of what&#8217;s possible,&#8221;
&#8220;Just this year, we&#8217;ve brought on some of the best and brightest executives in the world. They could go just about anywhere, but they believe Cloudflare is the next iconic technology company. They&#8217;re betting their careers on Cloudflare and joining us to further accelerate our growth.&#8221;
This week, the company disclosed the acquisition of Kivera, a cloud security, data protection, and compliance platform, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41227938/cloudflare-acquires-kivera-to-deliver-simple-preventive-cloud-security" rel="noreferrer noopener">for an undisclosed amount</a>.
By integrating Kivera with the Cloudflare One platform, the company aims to enhance cloud security by embedding preventive controls directly into the cloud deployment process, reducing risks before they occur.
The company will announce&nbsp;third-quarter<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41239125/cloudflare-announces-date-of-third-quarter-2024-financial-results" rel="noreferrer noopener"> results on November 7, 2024</a>.
Investors can gain exposure to the stock&nbsp;via Spear Alpha ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>) and TrueShares Technology, AI &amp; Deep Learning ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRNZ#NYSE">LRNZ</a>).
Price Action: NET shares are up 9.21% at $92.77 at the last check Thursday.
Photo via T. Schneider/Shutterstock.com
Read Next:
<a target="_blank" href="https://www.benzinga.com//node/41270201" rel="noreferrer noopener">Delta&#8217;s Turbulent&nbsp;Q3: Mixed Results And Tech Troubles Cloud Holiday&nbsp;Outlook</a>

Equities

Large Cap

Management

Movers

LRNZ

SPRX

Cloudflare Taps ServiceNow Executive To Drive $5B Growth Ambition - What's Going On?

BMO Capital analyst Katja Jancic maintains Constellium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSTM#NYSE">CSTM</a>) with a Outperform and lowers the price target from $24 to $22.

CSTM

BMO Capital Maintains Outperform on Constellium, Lowers Price Target to $22

Needham analyst Mike Matson reiterates InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Hold.

Reiteration

INMD

Needham Reiterates Hold on InMode

<a href="https://www.youtube.com/watch?v=vJ8aEO6ggOs" title="https://www.youtube.com/watch?v=vJ8aEO6ggOs">https://www.youtube.com/watch?v=vJ8aEO6ggOs</a>

INTC

AMD Says New Chip Has As Many As 192 Processor Cores; Turin Will Perform Better Than Even New Intel Chips

AMD Exec Says Latest Server CPU Chips Built On Zen 5 Architecture That Offers About 37% Speed Gain For Advanced AI Data Crunching

Needham analyst Mike Matson reiterates ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Hold.

ICUI

Needham Reiterates Hold on ICU Medical

Former Google CEO <a href="https://www.benzinga.com/topic/eric-schmidt">Eric Schmidt</a> thinks we won&#8217;t be able to meet our climate goals. At a recent AI+Energy Summit, Schmidt <a href="https://www.youtube.com/watch?v=oC46CzxT750">said</a> he doesn&#8217;t believe we are organized enough to achieve big targets, like the U.S. reaching net-zero emissions by 2050. Instead, he thinks we should invest more in artificial intelligence (AI) and data centers, which he says could help solve the energy problem – but only if we are willing to make some trade-offs.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
</ul>
<h2 class="wp-block-heading">AI's Rising Energy Demand</h2>
AI is growing quickly, resulting in a huge energy demand. According to Schmidt, data centers – the facilities that power AI – will need much more electricity in the coming years. <a href="https://www.benzinga.com/partner/commodities/24/05/38814247/ai-data-center-power-requirements-increasing-demand-for-critical-materials-like-copper-and-ur">These centers need a steady power supply</a> and as AI systems get more advanced, the need for energy will keep increasing. Schmidt said that if we don't improve our energy infrastructure, the U.S. might run out of enough power for these demands within the next four years.
Schmidt admits that these energy-hungry AI systems could make it even harder to meet climate goals. But instead of slowing down AI growth to save energy, he thinks investing in AI could be the key to solving some of our biggest environmental challenges.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Betting on AI Instead of Conservation</h2>
At the AI summit, Schmidt said bluntly: "We&#8217;re not going to hit the climate goals anyway because we&#8217;re not organized to do it." He explained that while there are ways to make data centers more efficient, like using better batteries and reducing power losses, those measures won&#8217;t be enough to keep up with AI&#8217;s fast growth.&nbsp;
Instead of scaling back, he believes we should push AI development to find solutions that traditional methods can&#8217;t provide.
Nevertheless, he says, &#8220;Because it&#8217;s a universal technology and because it&#8217;s the arrival of an alien intelligence, something we don&#8217;t understand, we may make mistakes concerning how it's used. But I can assure you that we&#8217;re not going to get there through conservation.&#8221;
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Nuclear Power and Rapid Infrastructure Development</h2>
Schmidt has also called for more nuclear power to support AI&#8217;s energy needs. He criticized decisions to shut down working nuclear plants in places like Germany and <a href="https://www.benzinga.com/markets/esg/24/08/40589781/power-hungry-ai-revives-interest-in-nuclear-energy-michigan-to-reopen-closed-plant-for-first-time-in">California</a>, saying nuclear energy is important for providing the stable, constant power that AI needs.&nbsp;
Renewables like solar and wind are helpful, but Schmidt said their unreliability means they can't handle the basic power needs required for AI growth alone.
He also pointed out that the current rules and regulations make it hard to build new energy infrastructure fast enough. Schmidt said the long approval process for new power lines and <a href="https://www.benzinga.com/startups/24/09/40669041/bill-gates-is-bringing-the-most-advanced-nuclear-facility-in-the-world-to-a-small-city-with-only-2-0">nuclear plants in the U.S.</a>, which can take more than ten years, is a major problem.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Other Controversial Stances</h2>
Schmidt is known for making controversial statements. During a recent talk at Stanford University, he suggested that if TikTok were banned in the U.S., <a href="https://www.benzinga.com/startups/24/08/40507961/ex-google-ceo-schmidt-told-students-to-steal-tiktoks-ip-hire-a-whole-bunch-of-lawyers-to-clean-the-m">students should use AI</a> to create a copy of the app, even recommending that they "steal users and music" and hire lawyers if it became successful.&nbsp;
He also <a href="https://www.benzinga.com/news/24/08/40357903/google-co-founder-eric-schmidt-blames-work-from-home-flexible-hours-for-falling-behind-openai-praise">criticized Google's focus on work-life balance</a> and remote work, saying it disadvantaged the company compared to more competitive AI startups like OpenAI.&nbsp;
Read Next:
<ul>
<li>Groundbreaking trading app with a ‘Buy-Now-Pay-Later' feature for stocks tackles the $644 billion margin lending market –<a href="https://www.benzinga.com/money/wolfpack"> here&#8217;s how to get equity in it with just $500</a></li>
<li>Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million with just $500</a>.</li>
</ul>

Startups

Former Google CEO Eric Schmidt Says 'We Are Never Going To Meet Our Climate Goals' – Pushes For AI And Data Centers To Solve The Crisis

SRPT

Sarepta Therapeutics shares are trading higher after Raymond James reinstated an Outperform rating on the stock and announced a price target of $150.

Stephens &amp; Co. analyst Andrew Terrell reiterates First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) with a Overweight and maintains $36 price target.

FIBK

Stephens & Co. Reiterates Overweight on First Interstate BancSys, Maintains $36 Price Target

Illumina introduces new DNA sequencing instruments, but Street unimpressed

10x Genomics plummets 27% after hours following Q3 preliminary earnings miss

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), 10x Genomic...

Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), 10x Genomics (TXG)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 10x Genomics (TXG – Research Report), Dyne Therapeut...

Analysts' Top Healthcare Picks: 10x Genomics (TXG), Dyne Therapeutics (DYN)

10x Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from ...

10x Genomics: Hold Rating Amidst Q3 Revenue Shortfall and Growth Uncertainty

Biggest stock movers Thursday: GXO, TXG, and more

Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Buy rating on 10x Genomics (TXG – Research Report). The associated price target ...

Buy Rating Affirmed for 10x Genomics Amidst Long-Term Growth Potential Despite Short-Term Challenges

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target ...

Stifel Nicolaus Sticks to Their Buy Rating for 10x Genomics (TXG)

TD Cowen analyst Daniel Brennan maintained a Hold rating on 10x Genomics (TXG – Research Report) today and set a price target of $20.00. The compan...

TD Cowen Sticks to Its Hold Rating for 10x Genomics (TXG)

Biggest stock movers Thursday: TLRY, GXO, TXG, and more

ALNY

CRWD

ETWO

EVGO

FSLR

ILMN

RLAY

TLRY

Press Releases

New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies

10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases

Earnings

10x Genomics Reports Second Quarter 2024 Financial Results

10x Genomics Announces Senior Leadership Changes

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

Waters

West Pharmaceutical Services, Inc. Common Stock

Comments

10x Genomics

Intérêt court

10x Genomics (NASDAQ:TXG) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL